Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
687 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01890746 | A Safety and Efficacy Study of Eltrombopag in Subjects With AML | completed | Phase 2 | 148 | Novartis PharmaceuticalsINDUSTRY | 10 | Sep 11, 2019 | clinicaltrials |
| NCT02518113 | A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBL | completed | Phase 1 / Phase 2 | 36 | Eli Lilly and CompanyINDUSTRY | 5 | Sep 11, 2019 | clinicaltrials |
| NCT02249429 |
| Open-Label, Non Randomized Phase 2 Study With Safety Run-In |
| completed |
| Phase 2 |
| 53 |
| PIQUR Therapeutics AGINDUSTRY |
| 6 |
| Sep 6, 2019 |
| clinicaltrials |
| NCT02294786 | Study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib With Capecitabine for the Treatment of Metastatic Breast Cancer | terminated | Phase 2 | 62 | Novartis PharmaceuticalsINDUSTRY | 5 | Jul 15, 2019 | clinicaltrials |
| NCT02023697 | Standard Dose Versus High Dose and Versus Extended Standard Dose Radium-223 Dichloride in Castration-resistant Prostate Cancer Metastatic to the Bone | completed | Phase 2 | 391 | BayerINDUSTRY | 15 | Jul 12, 2019 | clinicaltrials |
| NCT00826150 | Phase 1/2a Study of DTA-H19 in Advanced Stage Ovarian Cancer | completed | Phase 1 / Phase 2 | 14 | Anchiano Therapeutics Israel Ltd.INDUSTRY | 1 | Jun 13, 2019 | clinicaltrials |
| NCT01367665 | STEVIE: A Study of Vismodegib in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma | completed | Phase 2 | 1,232 | Hoffmann-La RocheINDUSTRY | 37 | Jun 6, 2019 | clinicaltrials |
| NCT00595088 | Phase 2b, Trial of Intravesical DTA-H19/PEI in Patients With Intermediate-Risk Superficial Bladder Cancer | completed | Phase 2 | 47 | Anchiano Therapeutics Israel Ltd.INDUSTRY | 2 | Apr 30, 2019 | clinicaltrials |
| NCT02747732 | Study of Ibrutinib in Combination With Bendamustine and Rituximab for Patients With Relapsed/Refractory Aggressive BCL | unknown | Phase 2 | 72 | Meirav Kedmi MDOTHER_GOV | 1 | Apr 23, 2019 | clinicaltrials |
| NCT03569696 | Improving the Outcome of High-risk Aggressive B-cell Lymphoma Patients With Nivolumab Maintenance Therapy(NivoM) | unknown | Phase 2 | 50 | Meirav Kedmi MDOTHER_GOV | 1 | Apr 23, 2019 | clinicaltrials |
| NCT03070574 | Mesalamine for Colorectal Cancer Prevention Program in Lynch Syndrome(MesaCAPP) | terminated | Phase 2 | 8 | Christoph GascheOTHER | 6 | Apr 18, 2019 | clinicaltrials |
| NCT03919461 | Colorectal Metastasis Prevention International Trial 2(COMPIT-2) | recruiting | Phase 2 | 200 | Assaf-Harofeh Medical CenterOTHER_GOV | 1 | Apr 18, 2019 | clinicaltrials |
| NCT01988077 | Clinical Evaluation of Yervoy in Combination With Adoptive T Cell Transfer for Metastatic Melanoma Patients | terminated | Phase 2 | 2 | Sheba Medical CenterOTHER_GOV | 1 | Apr 5, 2019 | clinicaltrials |
| NCT02632786 | The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis(PRONTO) | completed | Phase 2 | 129 | Prothena Biosciences Ltd.INDUSTRY | 10 | Apr 5, 2019 | clinicaltrials |
| NCT03412526 | Adoptive Cell Therapy Following a Reduced Intensity, Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Ovarian | unknown | Phase 2 | 15 | Sheba Medical CenterOTHER_GOV | 1 | Apr 4, 2019 | clinicaltrials |
| NCT03154047 | Study in Subjects With Light Chain (AL) Amyloidosis | terminated | Phase 2 | 80 | Prothena Biosciences Ltd.INDUSTRY | 10 | Mar 26, 2019 | clinicaltrials |
| NCT03221634 | Efficacy and Safety Study of Pembrolizumab (MK-3475) in Combination With Daratumumab in Participants With Relapsed Refractory Multiple Myeloma (MK-3475-668/KEYNOTE-668) | withdrawn | Phase 2 | 0 | Merck Sharp & Dohme LLCINDUSTRY | 6 | Mar 25, 2019 | clinicaltrials |
| NCT00711997 | Phase 1/2a DTA-H19 in Patients With Unresectable Pancreatic Cancer | completed | Phase 1 / Phase 2 | 9 | Anchiano Therapeutics Israel Ltd.INDUSTRY | 2 | Mar 20, 2019 | clinicaltrials |
| NCT02472145 | An Efficacy and Safety Study of Decitabine (DACOGEN) Plus Talacotuzumab (JNJ-56022473; Anti CD123) Versus Decitabine (DACOGEN) Alone in Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy | completed | Phase 2 / Phase 3 | 326 | Janssen Research & Development, LLCINDUSTRY | 14 | Mar 19, 2019 | clinicaltrials |
| NCT01907100 | Nintedanib (BIBF 1120) in Mesothelioma | terminated | Phase 2 / Phase 3 | 545 | Boehringer IngelheimINDUSTRY | 27 | Mar 18, 2019 | clinicaltrials |
| NCT01959282 | A Study of Safety and Effectiveness of JNJ-54781532 in Patients With Moderately to Severely Active Ulcerative Colitis | completed | Phase 2 | 219 | Janssen Research & Development, LLCINDUSTRY | 14 | Jan 4, 2019 | clinicaltrials |
| NCT03219671 | Nivolumab and Ipilimumab in Classical Kaposi Sarcoma (CKS) | unknown | Phase 2 | 20 | Alona ZerOTHER | 1 | Dec 26, 2018 | clinicaltrials |
| NCT01055197 | Radiation Therapy in Treating Patients With Extensive Stage Small Cell Lung Cancer | completed | Phase 2 | 97 | Radiation Therapy Oncology GroupNETWORK | 3 | Dec 12, 2018 | clinicaltrials |
| NCT00604136 | Treatment of Metastatic Melanoma With Tumor Infiltrating Lymphocytes and IL-2 Following Lympho-depleting Chemotherapy | unknown | Phase 2 | 20 | Hadassah Medical OrganizationOTHER | 1 | Sep 18, 2018 | clinicaltrials |
| NCT01174563 | A Study on the Correlation Between Tarceva (Erlotinib) - Induced Rash and Efficacy in EGFR Mutated Participants With Advanced Non-Small Cell Lung Cancer Receiving First-Line Therapy | completed | Phase 2 | 60 | Hoffmann-La RocheINDUSTRY | 1 | Sep 17, 2018 | clinicaltrials |
| NCT01923168 | Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women | completed | Phase 2 | 340 | Novartis PharmaceuticalsINDUSTRY | 17 | Sep 14, 2018 | clinicaltrials |
| NCT00915018 | Study Evaluating Neratinib Plus Paclitaxel VS Trastuzumab Plus Paclitaxel In ErbB-2 Positive Advanced Breast Cancer(NEFERTT) | completed | Phase 2 | 479 | Puma Biotechnology, Inc.INDUSTRY | 35 | Aug 22, 2018 | clinicaltrials |
| NCT00809211 | Nilotinib in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia | completed | Phase 2 | 40 | Cancer Trials IrelandNETWORK | 4 | Jul 24, 2018 | clinicaltrials |
| NCT00074087 | Liposomal Doxorubicin in Treating Patients With Stage IIB, Stage IVA, or Stage IVB Recurrent or Refractory Mycosis Fungoides | completed | Phase 2 | 49 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 6 | Jul 9, 2018 | clinicaltrials |
| NCT01113957 | A Trial of ABT-888 in Combination With Temozolomide Versus Pegylated Liposomal Doxorubicin Alone in Ovarian Cancer | completed | Phase 2 | 168 | AbbVie (prior sponsor, Abbott)INDUSTRY | 8 | Jun 6, 2018 | clinicaltrials |
| NCT01263704 | A Study of MabThera/Rituxan (Rituximab) in Combination With Fludarabine And Cyclophosphamide as Primary Therapy in Elderly Patients With Chronic Lymphocytic Leukemia | completed | Phase 2 | 42 | Hoffmann-La RocheINDUSTRY | 1 | Apr 23, 2018 | clinicaltrials |
| NCT01627795 | Safety and Efficacy of Oshadi D and Oshadi R for Malignant Mesothelioma Treatment | suspended | Phase 1 / Phase 2 | 17 | Oshadi Drug AdministrationINDUSTRY | 1 | Apr 18, 2018 | clinicaltrials |
| NCT02007317 | Safety and Efficacy of Oshadi D and Oshadi R in Basal Cell Carcinoma Patients Prior to Tumor Excision a Phase 2 Study | completed | Phase 2 | 30 | Oshadi Drug AdministrationINDUSTRY | 1 | Apr 18, 2018 | clinicaltrials |
| NCT02134990 | Oshadi D and Oshadi R in Combination With Docetaxel, as 2nd Line Therapy for Metastatic Non Small Cell Lung Cancer | unknown | Phase 2 | 20 | Oshadi Drug AdministrationINDUSTRY | 1 | Apr 18, 2018 | clinicaltrials |
| NCT01934790 | Re-treatment Safety of Radium-223 Dichloride in Castration-resistant Prostate Cancer With Bone Metastases | completed | Phase 1 / Phase 2 | 45 | BayerINDUSTRY | 7 | Mar 26, 2018 | clinicaltrials |
| NCT02654041 | Study of Induction of Hypothyroxinemia Adjunct to Conventional Therapies in GBM Patients | terminated | Phase 2 | 3 | Musli Thyropeutics Ltd.INDUSTRY | 1 | Mar 22, 2018 | clinicaltrials |
| NCT01024036 | A Study to Evaluate the Efficacy and Safety of CNTO328 Plus Best Supportive Care in Multicentric Castleman's Disease | completed | Phase 2 | 79 | Janssen Research & Development, LLCINDUSTRY | 23 | Mar 21, 2018 | clinicaltrials |
| NCT01400620 | Safety and Efficacy of IZN-6N4 Oral Rinse for the Prevention of Oral Mucositis in Patients With Head and Neck Cancer | completed | Phase 2 | 110 | Izun Pharma LtdINDUSTRY | 2 | Mar 13, 2018 | clinicaltrials |
| NCT01453205 | A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | completed | Phase 2 | 187 | MedImmune LLCINDUSTRY | 11 | Mar 12, 2018 | clinicaltrials |
| NCT02239731 | Safety, Tolerability and Efficacy Study of Doxycycline Foam for the Prevention of EGFRI Skin Toxicity in Cancer Patients | completed | Phase 2 | 24 | Vyne Therapeutics Inc.INDUSTRY | 1 | Feb 27, 2018 | clinicaltrials |
| NCT00388700 | A New Agent GM-CT-01 in Combination With 5-FU, Avastin and Leucovorin in Subjects With Colorectal Cancer | withdrawn | Phase 2 | 0 | Galectin Therapeutics Inc.INDUSTRY | 1 | Feb 14, 2018 | clinicaltrials |
| NCT02119676 | Study of Ruxolitinib in Colorectal Cancer Patients | terminated | Phase 2 | 396 | Incyte CorporationINDUSTRY | 8 | Feb 13, 2018 | clinicaltrials |
| NCT01472887 | SAR3419 as Single Agent in Relapsed-Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients(STARLYTE) | completed | Phase 2 | 61 | SanofiINDUSTRY | 9 | Jan 25, 2018 | clinicaltrials |
| NCT01693068 | Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma | completed | Phase 2 | 194 | EMD SeronoINDUSTRY | 14 | Jan 5, 2018 | clinicaltrials |
| NCT01724242 | Vaginal DHEA for Women After Breast Cancer | withdrawn | Phase 2 / Phase 3 | 0 | Hadassah Medical OrganizationOTHER | 1 | Nov 28, 2017 | clinicaltrials |
| NCT03096912 | A Study Assessing Efficacy & Safety of Ribociclib in Patients With Advanced Well/Dedifferentiated Liposarcoma | unknown | Phase 2 | 30 | Assaf-Harofeh Medical CenterOTHER_GOV | 1 | Oct 25, 2017 | clinicaltrials |
| NCT02488382 | Lonquek for Autologous Stem Cell Mobilization | unknown | Phase 1 / Phase 2 | 24 | Sheba Medical CenterOTHER_GOV | 1 | Oct 17, 2017 | clinicaltrials |
| NCT02278133 | Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway Mutations | completed | Phase 1 / Phase 2 | 20 | Array BioPharmaINDUSTRY | 10 | Oct 9, 2017 | clinicaltrials |
| NCT02544438 | Study Evaluating the Safety and Efficacy of Astarabine in Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia(BSTPHASE1-01) | completed | Phase 1 / Phase 2 | 20 | BioSight Ltd.INDUSTRY | 1 | Sep 27, 2017 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials